Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study

Y. Tang, T. A. Glauser, D. L. Gilbert, A. D. Hershey, M. D. Privitera, D. M. Ficker, J. P. Szaflarski, Frank R Sharp

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Objective - Valproic acid (VPA) is a commonly used anticonvulsant with multiple systemic effects. The purpose of this pilot study is to examine the blood genomic expression pattern associated with VPA therapy in general and secondly VPA efficacy in children with epilepsy. Materials and methods - Using oligonucleotide microarrays, gene expression in whole blood was assessed in pediatric epilepsy patients following treatment with VPA compared with children with epilepsy prior to initiation of anticonvulsant therapy (drug free patients). Results - The expression of 461 genes was altered in VPA patients (n = 11) compared with drug free patients (n = 7), among which a significant number of serine threonine kinases were down-regulated. Expression patterns in children seizure free on VPA therapy (n = 8) demonstrated 434 up-regulated genes, many in mitochondria, compared with VPA children with continuing seizures (n = 3) and drug free seizure patients (n = 7). Conclusion - VPA therapy is associated with two significant and unique blood gene expression patterns: chronic VPA monotherapy in general and a separate blood genomic profile correlated with seizure freedom. These expression patterns provide new insight into previously undetected mechanisms of VPA anticonvulsant activity.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalActa Neurologica Scandinavica
Volume109
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Valproic Acid
Epilepsy
Seizures
Anticonvulsants
Gene Expression
Therapeutics
Protein-Serine-Threonine Kinases
Oligonucleotide Array Sequence Analysis
Pharmaceutical Preparations
Mitochondria
Pediatrics

Keywords

  • Anticonvulsant
  • Blood marker
  • Carbamazepine
  • Epilepsy
  • Gene expression
  • Microarray
  • Seizure
  • Valproic Acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study. / Tang, Y.; Glauser, T. A.; Gilbert, D. L.; Hershey, A. D.; Privitera, M. D.; Ficker, D. M.; Szaflarski, J. P.; Sharp, Frank R.

In: Acta Neurologica Scandinavica, Vol. 109, No. 3, 03.2004, p. 159-168.

Research output: Contribution to journalArticle

Tang, Y, Glauser, TA, Gilbert, DL, Hershey, AD, Privitera, MD, Ficker, DM, Szaflarski, JP & Sharp, FR 2004, 'Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study', Acta Neurologica Scandinavica, vol. 109, no. 3, pp. 159-168. https://doi.org/10.1046/j.1600-0404.2003.00253.x
Tang, Y. ; Glauser, T. A. ; Gilbert, D. L. ; Hershey, A. D. ; Privitera, M. D. ; Ficker, D. M. ; Szaflarski, J. P. ; Sharp, Frank R. / Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study. In: Acta Neurologica Scandinavica. 2004 ; Vol. 109, No. 3. pp. 159-168.
@article{3947033321d646d9a834f2dda53a1ba2,
title = "Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study",
abstract = "Objective - Valproic acid (VPA) is a commonly used anticonvulsant with multiple systemic effects. The purpose of this pilot study is to examine the blood genomic expression pattern associated with VPA therapy in general and secondly VPA efficacy in children with epilepsy. Materials and methods - Using oligonucleotide microarrays, gene expression in whole blood was assessed in pediatric epilepsy patients following treatment with VPA compared with children with epilepsy prior to initiation of anticonvulsant therapy (drug free patients). Results - The expression of 461 genes was altered in VPA patients (n = 11) compared with drug free patients (n = 7), among which a significant number of serine threonine kinases were down-regulated. Expression patterns in children seizure free on VPA therapy (n = 8) demonstrated 434 up-regulated genes, many in mitochondria, compared with VPA children with continuing seizures (n = 3) and drug free seizure patients (n = 7). Conclusion - VPA therapy is associated with two significant and unique blood gene expression patterns: chronic VPA monotherapy in general and a separate blood genomic profile correlated with seizure freedom. These expression patterns provide new insight into previously undetected mechanisms of VPA anticonvulsant activity.",
keywords = "Anticonvulsant, Blood marker, Carbamazepine, Epilepsy, Gene expression, Microarray, Seizure, Valproic Acid",
author = "Y. Tang and Glauser, {T. A.} and Gilbert, {D. L.} and Hershey, {A. D.} and Privitera, {M. D.} and Ficker, {D. M.} and Szaflarski, {J. P.} and Sharp, {Frank R}",
year = "2004",
month = "3",
doi = "10.1046/j.1600-0404.2003.00253.x",
language = "English (US)",
volume = "109",
pages = "159--168",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Valproic acid blood genomic expression patterns in children with epilepsy - A pilot study

AU - Tang, Y.

AU - Glauser, T. A.

AU - Gilbert, D. L.

AU - Hershey, A. D.

AU - Privitera, M. D.

AU - Ficker, D. M.

AU - Szaflarski, J. P.

AU - Sharp, Frank R

PY - 2004/3

Y1 - 2004/3

N2 - Objective - Valproic acid (VPA) is a commonly used anticonvulsant with multiple systemic effects. The purpose of this pilot study is to examine the blood genomic expression pattern associated with VPA therapy in general and secondly VPA efficacy in children with epilepsy. Materials and methods - Using oligonucleotide microarrays, gene expression in whole blood was assessed in pediatric epilepsy patients following treatment with VPA compared with children with epilepsy prior to initiation of anticonvulsant therapy (drug free patients). Results - The expression of 461 genes was altered in VPA patients (n = 11) compared with drug free patients (n = 7), among which a significant number of serine threonine kinases were down-regulated. Expression patterns in children seizure free on VPA therapy (n = 8) demonstrated 434 up-regulated genes, many in mitochondria, compared with VPA children with continuing seizures (n = 3) and drug free seizure patients (n = 7). Conclusion - VPA therapy is associated with two significant and unique blood gene expression patterns: chronic VPA monotherapy in general and a separate blood genomic profile correlated with seizure freedom. These expression patterns provide new insight into previously undetected mechanisms of VPA anticonvulsant activity.

AB - Objective - Valproic acid (VPA) is a commonly used anticonvulsant with multiple systemic effects. The purpose of this pilot study is to examine the blood genomic expression pattern associated with VPA therapy in general and secondly VPA efficacy in children with epilepsy. Materials and methods - Using oligonucleotide microarrays, gene expression in whole blood was assessed in pediatric epilepsy patients following treatment with VPA compared with children with epilepsy prior to initiation of anticonvulsant therapy (drug free patients). Results - The expression of 461 genes was altered in VPA patients (n = 11) compared with drug free patients (n = 7), among which a significant number of serine threonine kinases were down-regulated. Expression patterns in children seizure free on VPA therapy (n = 8) demonstrated 434 up-regulated genes, many in mitochondria, compared with VPA children with continuing seizures (n = 3) and drug free seizure patients (n = 7). Conclusion - VPA therapy is associated with two significant and unique blood gene expression patterns: chronic VPA monotherapy in general and a separate blood genomic profile correlated with seizure freedom. These expression patterns provide new insight into previously undetected mechanisms of VPA anticonvulsant activity.

KW - Anticonvulsant

KW - Blood marker

KW - Carbamazepine

KW - Epilepsy

KW - Gene expression

KW - Microarray

KW - Seizure

KW - Valproic Acid

UR - http://www.scopus.com/inward/record.url?scp=1442300774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442300774&partnerID=8YFLogxK

U2 - 10.1046/j.1600-0404.2003.00253.x

DO - 10.1046/j.1600-0404.2003.00253.x

M3 - Article

C2 - 14763951

AN - SCOPUS:1442300774

VL - 109

SP - 159

EP - 168

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 3

ER -